LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quar…
Author: Business Wire
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quar…
Sightview Offers ASCRS 2026 Attendees Early Access to Enhanced EHR Solution
DURHAM, N.C.–(BUSINESS WIRE)– #ASCRS2026–Sightview will offer early demo access to its new flagship EHR platform at the 2026 ASCRS Annual Meeting.
Ollin Biosciences to Participate in Two Upcoming Investor Conferences
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two…
Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AurionBiotech–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated,…
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clea…
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release firs…
GenSight Biologics publie sa situation de trésorerie et les revenus du programme d’Autorisation d’Accès Compassionnel (AAC) au 31 mars 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Systane se joint aux Blue Jays de Toronto à titre de goutte oculaire officielle pour sensibiliser les Canadiens à la sécheresse oculaire
TORONTO–(BUSINESS WIRE)–Cette saison, Alcon, le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé un partenariat entre les Blue Jays de Toronto et SystaneMD en tant que gouttes oculaires…
Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada
TORONTO–(BUSINESS WIRE)–This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help…
ForSight Robotics Makes History with the World’s First-in-Human Fully Robot-Assisted Cataract Surgery
CAESAREA, Israel–(BUSINESS WIRE)–ForSight Robotics, the global pioneer in robotic eye surgery, today announced the successful completion of the world’s first fully robot-assisted cataract surgery performed in a human patient using its proprietary JAS…
Tenpoint Therapeutics, Ltd. Appoints Stephen S. Lane, M.D., as Chief Medical Officer
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment of Stephen S. Lane…
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy ful…
Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that …
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place du…
Alcon Publishes Agenda for 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2026 Annual General Meeting
Alcon Publishes Agenda for 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2026 Annual General Meeting
Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program to Make Novel Presbyopia Therapy More Accessible and Affordable
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, th…